MassIVE MSV000091158

Partial Public PXD039690

Identification of phosphorylation sites regulated by lysophosphatidic acid (LPA) in OVCAR8 ovarian cancer cells

Subscribe Comment Convert Spectra Add Reanalysis

Description

Elevated levels of lysophosphatidic acid (LPA) species accumulate in the ascites of ovarian high grade serous cancer (HGSC) and are associated with a short relapse-free survival. LPA is known to support the metastatic spread of cancer cells by activating a multitude of signaling pathways through G-protein-coupled receptors of the LPAR family. Systematic unbiased analyses of the LPA-regulated signal transduction network in ovarian cancer cells have, however, not been reported to date. Methods: LPA-induced signaling pathways were identified by phosphoproteomics of both patient-derived cells and the HGSC cell line OVCAR8, RNA sequencing, pharmacological inhibition, measurements of intracellular Ca2+ and cAMP levels as well as cell imaging. The function of LPARs and downstream signaling components in migration and the formation of entotic cell-in-cell structures was analyzed by applying selective pharmacological inhibitors and RNA interference. Results: Transcriptional signaling by LPA is mainly mediated by LPAR1 to target genes promoting cell motility and migration via multiple cooperating pathways, including PKC, PKD1 and ERK1/2, as demonstrated for IL6 and THBS1 genes. Likewise, cytoplasmic signaling targeting actomyosin is mediated by interconnected phosphorylation-driven pathways triggered prominently by LPAR1. A central component of these signaling pathways is the protein phosphatase 1 regulatory subunit MYPT1, which is a negative regulator of myosin light chain 2 (MYL2). MYPT1 is negatively regulated by PKC- and ERK-mediated phosphorylation in response to LPA, and is indispensable for LPA-induced actomyosin-dependent cell migration and entosis (cell-in-cell invasion). We further show a novel LPAR2-DOCK7 pathway to be essential for the induction of entosis. Conclusion: The LPAR1-ERK/PKC-MYPT1 axis is a critical pathway of LPA-triggered cytoskeletal changes, cell migration and entotic cell-in-cell invasion, pointing to MYPT1 as a promising candidate for therapeutic intervention. For phosphoproteomic analyses cells were treated with LPA, antagonists or solvent at least in triplicate and lysed in 100 mM Tris pH 7.6, 4% SDS, PhosSTOP (Roche, #4906845001), Protease Inhibitor Cocktail (Sigma, P8340). Analysis of OVCAR8 lysates proceeded as follows: samples were subjected to acetone precipitation and following tryptic digest of 600 ug total protein per sample as described [PMID: 33391540], as well as desalting using Waters Oasis HLB cartridges (Waters, #186006339) and peptide yield determination using the Quantitative Fluorometric Peptide Assay (Pierce, #23290), each sample was labeled using TMTsixplex (Thermo Scientific, #90064) following the manufacturer's protocol. Subsequent to mass spectrometric validation of labeling efficiency and mixing 80 ug peptides per channel using samples from solvent control experiments as bridging samples where more than a single sixplex was required to cover replicate experiments, multiplexed samples were desalted once more as described above. Of the resulting pooled samples, 30 ug each where fractionated into eight fractions using High pH Reversed-Phase Peptide Fractionation Kit (Pierce, #84868) using the manufacturer's protocol and evaporation to dryness for subsequent analysis of the background proteome. In the remaining multiplexed peptide samples, phosphorylated peptides where enriched using the High-Select Fe-NTA Phosphopeptide Enrichment Kit (Thermo Scientific, #A32992). While 5% (10 ul) of the resulting eluate where evaporated to dryness for direct subsequent liquid chromatography/tandem mass spectrometry (LC-MS2) analysis, the remainder was once more separated into eight fractions using the High pH Reversed-Phase Peptide Fractionation Kit and fractions subsequently evaporated to dryness. LC-MS2 analysis was performed on 50% of the corresponding sample material rehydrated in 0.1% formic acid as published [PMID: 33391540]. Detailed information on instrumentation parametrization was extracted and summarized using MARMoSET [PMID: 31097673] and is included in the repository-deposited data set. Peptide/spectrum matching as well as TMT quantitation was performed using the MaxQuant suit of algorithms (version 2.0.3.0 [PMID: 19029910]) against the human canonical and isoforms Uniprot database (downloaded 20211026, 202160 entries). Mass spectrometric raw data along with documentation of instrumentation parameters governing its acquisition as well as MaxQuant parameters employed are deposited. Data were filtered for rows containing no zero values, and analyzed by paired Student's t-test (blocking on replicate set / phosphoproteome analysis chip). Thresholds were set according to the dynamic range of the assay to FC >1.2x or <0.83x and p <0.1. [doi:10.25345/C5PC2TK19] [dataset license: CC0 1.0 Universal (CC0 1.0)]

Keywords: lysophosphatidic acid ; phosphoproteome ; signal transduction ; protein kinases ; ovarian cancer metastasis ; actomyosin dynamics ; entosis ; protein phosphatase 1 regulatory subunit MYPT1 ; DOCK7

Contact

Principal Investigators:
(in alphabetical order) 		Rolf Mueller, Center for Tumor Biology and Immunology (ZTI), Philipps University Marburg, Germany
Submitting User: graumann

Publications

Kaire Ojasalu, Sonja Lieber, Anna M. Sokol, Andrea Nist, Thorsten Stiewe, Imke Bullwinkel, Florian Finkernagel, Silke Reinartz, Sabine Müller-Brüsselbach, Robert Grosse, Johannes Graumann, Rolf Müller.
The lysophosphatidic acid-regulated signal transduction network in ovarian cancer cells and its role in actomyosin dynamics, cell migration and entosis.
Theranostics. 2023 Mar 21;13(6):1921-1948. doi: 10.7150/thno.81656. eCollection 2023.

Number of Files:
Total Size:
Spectra:
Subscribers:
 
Owner Reanalyses
Experimental Design
    Conditions:
    Biological Replicates:
    Technical Replicates:
 
Identification Results
    Proteins (Human, Remapped):
    Proteins (Reported):
    Peptides:
    Variant Peptides:
    PSMs:
 
Quantification Results
    Differential Proteins:
    Quantified Proteins:
 
Browse Dataset Files
 
FTP Download Link (click to copy):

Species

Instrument

Modifications

- Dataset Reanalyses

+ Dataset History

Click here to queue conversion of this dataset's submitted spectrum files to open formats (e.g. mzML). This process may take some time.

When complete, the converted files will be available in the "ccms_peak" subdirectory of the dataset's FTP space (accessible via the "FTP Download" link to the right).
Number of distinct conditions across all analyses (original submission and reanalyses) associated with this dataset.

Distinct condition labels are counted across all files submitted in the "Metadata" category having a "Condition" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct biological replicates across all analyses (original submission and reanalyses) associated with this dataset.

Distinct replicate labels are counted across all files submitted in the "Metadata" category having a "BioReplicate" or "Replicate" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct technical replicates across all analyses (original submission and reanalyses) associated with this dataset.

The technical replicate count is defined as the maximum number of times any one distinct combination of condition and biological replicate was analyzed across all files submitted in the "Metadata" category. In the case of fractionated experiments, only the first fraction is considered.

"N/A" means no results of this type were submitted.
Originally identified proteins that were automatically remapped by MassIVE to proteins in the SwissProt human reference database.

"N/A" means no results of this type were submitted.
Number of distinct protein accessions reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct unmodified peptide sequences reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct peptide sequences (including modified variants or peptidoforms) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Total number of peptide-spectrum matches (i.e. spectrum identifications) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins quantified across all analyses (original submission and reanalyses) associated with this dataset.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins found to be differentially abundant in at least one comparison across all analyses (original submission and reanalyses) associated with this dataset.

A protein is differentially abundant if its change in abundance across conditions is found to be statistically significant with an adjusted p-value <= 0.05 and lists no issues associated with statistical tests for differential abundance.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
This dataset may not contain all raw spectra data as originally deposited in PRIDE. It has been imported to MassIVE for reanalysis purposes, so its spectra data here may consist solely of processed peak lists suitable for reanalysis with most software.